An enantioselective intramolecular oxidative cyclization of 4-alkenoic acids was developed. The reaction proceeded via a π-allyl Pd intermediate generated by an allylic C–H activation to give γ-lactone derivatives with moderate to good enantioselectivity. Spiro bis(isoxazoline) ligand, SPRIX, was indispensable for this asymmetric transformation.
A copper-catalyzedasymmetricallylicsubstitution of γ,γ-disubstituted allylphosphates with arylboronates has been developed for the construction of quaternary stereocenters. High regio- and enantioselectivities have been achieved by employing a hydroxy-bearing chiral N-heterocyclic carbene ligand, and both E and Z substrates provide the same enantiomer as the major product. The mechanistic aspect
Chiral Phosphoramide-Catalyzed Enantioselective Addition of Allylic Trichlorosilanes to Aldehydes. Preparative Studies with Bidentate Phosphorus-Based Amides
作者:Scott E. Denmark、Jiping Fu、Michael J. Lawler
DOI:10.1021/jo052203h
日期:2006.2.1
that more than one Lewis basic moiety (phosphoramide) is involved in the rate- and stereochemistry-determining step of enantioselectiveallylation, bidentate chiral phosphoramides were developed. Different chiral phosphoramide moieties were connected by tethers of methylene chains of varying length. The rate and enantioselectivity of allylation with allyltrichlorosilane promoted by the bidentate phosphoramides
[EN] NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX DÉRIVÉS ARYLALCÉNYLPROPARGYLAMINE FAISANT PREUVE D'ACTION NEUROPROTECTRICE POUR LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
申请人:SEMMELWEIS EGYETEM
公开号:WO2015087094A1
公开(公告)日:2015-06-18
The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.
Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α<sub>2</sub>-Adrenoceptor Blocking Activity
作者:J. Ignacio Andrés、Jesús Alcázar、José M. Alonso、Rosa M. Alvarez、Margot H. Bakker、Ilse Biesmans、José M. Cid、Ana I. De Lucas、Javier Fernández、Luis M. Font、Koen A. Hens、Laura Iturrino、Ilse Lenaerts、Sonia Martínez、Anton A. Megens、Joaquín Pastor、Patrick C. M. Vermote、Thomas Steckler
DOI:10.1021/jm049619s
日期:2005.3.1
The synthesis and pharmacology of a new series of 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles that combine central serotonin (5-HT) reuptakeinhibition with alpha(2)-adrenoceptor blocking activity is described as potentialantidepressants. Four compounds were selected for further evaluation, and the combination of both activities was found to be stereoselective, residing mainly